Ferring Pharmaceuticals and RESOLVE: The National Infertility Association Join Together to Launch Nurse Liaison Program
Program to Launch During RESOLVE's National Infertility Awareness Week(R),
Nurses who enroll in the RESOLVE Nurse Liaison Program will receive e-communication on a regular basis with up-to-date patient education materials and other available resources. In addition, RESOLVE will periodically ask for feedback from nurses on the current state of patient education in infertility and gaps that they see in patient's knowledge. As a member of this valuable program, nurses will be prominently featured on RESOLVE's Web site and have the opportunity to contribute articles and speak at RESOLVE events.
"RESOLVE is proud to collaborate with Ferring Pharmaceuticals especially during National Infertility Awareness Week(R). Our goal is to spread information about infertility and its treatments to those fighting the disease of infertility," said
"Ferring is pleased to be working with RESOLVE to give nurses the resources they need to enhance the patient care journey," said
Nurses who are interested in becoming a member of the RESOLVE Nurse Liaison Program can visit www.resolve.org/nurseprogram. Upon receipt of the registration form, RESOLVE will send a program welcome packet that outlines the details of the program.
About Ferring Pharmaceuticals
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned, international pharmaceutical company, manufactures and markets the largest family of fertility treatments in the U.S. The Company markets MENOPUR, BRAVELLE, REPRONEX(R) (menotropins for injection, USP), NOVAREL(R) (chorionic gonadotropin for injection, USP) and ENDOMETRIN(R) (progesterone) Vaginal Insert in the U.S. to infertility specialists and their patients. Ferring also offers the Q-CAP(TM), the first and only needle-free reconstitution device, for use with its fertility treatments.
Ferring's line of orthopaedic and urology products includes EUFLEXXA(R) (1% sodium hyaluronic acid) and PROSED(R) DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate). Other products include: ACTHREL(R) (corticorelin ovine triflutate for injection), DESMOPRESSIN and DEGARELIX for injection.
The Ferring Group specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/ gynecology, infertility and orthopaedics. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com.
About RESOLVE: The National Infertility Association
Founded in 1974, RESOLVE: The National Infertility Association, headquartered in
SOURCE Ferring Pharmaceuticals